IMMUNEONCO-B (01541) announced that on February 10, 2026, the company entered into a loan agreement with the borrower, Dr. Tian Wenzhi. Under the agreement, the company agreed to provide a loan with a principal amount of 13.7247 million yuan to the borrower. The terms of the loan agreement, including the applicable interest rate, were determined through fair negotiations between the company and the borrower, taking into account prevailing market rates and practices. The loan agreement was established after the company considered the following factors: the group maintains a strong financial position and possesses sufficient internal resources to fund the loan; providing the loan will not impact the group's working capital or daily operations; and the loan is expected to generate stable interest income.